Dokumentacja Integracyjna SMPL
25.0.0 - STU1 Poland flag

: ActiveSubstanceCodeCodeSystem - TTL Representation

Active as of 2024-09-17

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:CodeSystem ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "PLActiveSubstanceCodeCodeSystem"] ; # 
  fhir:meta [
    ( fhir:profile [
fhir:v "https://ezdrowie.gov.pl/fhir/StructureDefinition/PLSMPLAdminCodeSystem"^^xsd:anyURI ;
fhir:link <https://ezdrowie.gov.pl/fhir/StructureDefinition/PLSMPLAdminCodeSystem>     ] )
  ] ; # 
  fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem PLActiveSubstanceCodeCodeSystem</b></p><a name=\"PLActiveSubstanceCodeCodeSystem\"> </a><a name=\"hcPLActiveSubstanceCodeCodeSystem\"> </a><a name=\"PLActiveSubstanceCodeCodeSystem-pl-PL\"> </a><p>This case-sensitive code system <code>https://ezdrowie.gov.pl/fhir/CodeSystem/PLActiveSubstanceCodeCodeSystem</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">larotrektynib<a name=\"PLActiveSubstanceCodeCodeSystem-larotrektynib\"> </a></td><td>Larotrektynib</td></tr><tr><td style=\"white-space:nowrap\">cetuksymab<a name=\"PLActiveSubstanceCodeCodeSystem-cetuksymab\"> </a></td><td>Cetuksymab</td></tr><tr><td style=\"white-space:nowrap\">panitumumab<a name=\"PLActiveSubstanceCodeCodeSystem-panitumumab\"> </a></td><td>Panitumumab</td></tr><tr><td style=\"white-space:nowrap\">adalimumab<a name=\"PLActiveSubstanceCodeCodeSystem-adalimumab\"> </a></td><td>Adalimumab (dostępny w terapii pacjentów od 4 r.ż.)</td></tr><tr><td style=\"white-space:nowrap\">etanercept<a name=\"PLActiveSubstanceCodeCodeSystem-etanercept\"> </a></td><td>Etanercept (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td style=\"white-space:nowrap\">infliksymab<a name=\"PLActiveSubstanceCodeCodeSystem-infliksymab\"> </a></td><td>Infliksymab</td></tr><tr><td style=\"white-space:nowrap\">iksekizumab<a name=\"PLActiveSubstanceCodeCodeSystem-iksekizumab\"> </a></td><td>Iksekizumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td style=\"white-space:nowrap\">sekukinumab<a name=\"PLActiveSubstanceCodeCodeSystem-sekukinumab\"> </a></td><td>Sekukinumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td style=\"white-space:nowrap\">ustekinumab<a name=\"PLActiveSubstanceCodeCodeSystem-ustekinumab\"> </a></td><td>Ustekinumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td style=\"white-space:nowrap\">ryzankizumab<a name=\"PLActiveSubstanceCodeCodeSystem-ryzankizumab\"> </a></td><td>Ryzankizumab</td></tr><tr><td style=\"white-space:nowrap\">guselkumab<a name=\"PLActiveSubstanceCodeCodeSystem-guselkumab\"> </a></td><td>Guselkumab</td></tr><tr><td style=\"white-space:nowrap\">certolizumab_pegol<a name=\"PLActiveSubstanceCodeCodeSystem-certolizumab_pegol\"> </a></td><td>Certolizumab pegol</td></tr><tr><td style=\"white-space:nowrap\">tyldrakizumab<a name=\"PLActiveSubstanceCodeCodeSystem-tyldrakizumab\"> </a></td><td>Tyldrakizumab</td></tr><tr><td style=\"white-space:nowrap\">bimekizumab<a name=\"PLActiveSubstanceCodeCodeSystem-bimekizumab\"> </a></td><td>Bimekizumab</td></tr><tr><td style=\"white-space:nowrap\">esketamina<a name=\"PLActiveSubstanceCodeCodeSystem-esketamina\"> </a></td><td>Esketamina</td></tr><tr><td style=\"white-space:nowrap\">zanubrutynib<a name=\"PLActiveSubstanceCodeCodeSystem-zanubrutynib\"> </a></td><td>Zanubrutynib</td></tr><tr><td style=\"white-space:nowrap\">daratumumab<a name=\"PLActiveSubstanceCodeCodeSystem-daratumumab\"> </a></td><td>Daratumumab</td></tr><tr><td style=\"white-space:nowrap\">entrektynib<a name=\"PLActiveSubstanceCodeCodeSystem-entrektynib\"> </a></td><td>Entrektynib</td></tr><tr><td style=\"white-space:nowrap\">rytuksymab<a name=\"PLActiveSubstanceCodeCodeSystem-rytuksymab\"> </a></td><td>Rytuksymab</td></tr><tr><td style=\"white-space:nowrap\">efgartigimod_alfa<a name=\"PLActiveSubstanceCodeCodeSystem-efgartigimod_alfa\"> </a></td><td>Efgartigimod alfa</td></tr></table></div>"
  ] ; # 
  fhir:url [ fhir:v "https://ezdrowie.gov.pl/fhir/CodeSystem/PLActiveSubstanceCodeCodeSystem"^^xsd:anyURI] ; # 
  fhir:version [ fhir:v "25.0.0"] ; # 
  fhir:name [ fhir:v "PLActiveSubstanceCodeCodeSystem"] ; # 
  fhir:title [ fhir:v "ActiveSubstanceCodeCodeSystem"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:experimental [ fhir:v "false"^^xsd:boolean] ; # 
  fhir:date [ fhir:v "2024-09-17T15:37:37+02:00"^^xsd:dateTime] ; # 
  fhir:publisher [ fhir:v "CeZ"] ; # 
  fhir:contact ( [
fhir:name [ fhir:v "CeZ" ] ;
    ( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "https://ezdrowie.gov.pl" ]     ] )
  ] ) ; # 
  fhir:description [ fhir:v "Kody substancji czynnych"] ; # 
  fhir:jurisdiction ( [
    ( fhir:coding [
fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ;
fhir:code [ fhir:v "PL" ] ;
fhir:display [ fhir:v "Poland" ]     ] )
  ] ) ; # 
  fhir:caseSensitive [ fhir:v "true"^^xsd:boolean] ; # 
  fhir:content [ fhir:v "complete"] ; # 
  fhir:count [ fhir:v "20"^^xsd:nonNegativeInteger] ; # 
  fhir:concept ( [
fhir:code [ fhir:v "larotrektynib" ] ;
fhir:display [ fhir:v "Larotrektynib" ]
  ] [
fhir:code [ fhir:v "cetuksymab" ] ;
fhir:display [ fhir:v "Cetuksymab" ]
  ] [
fhir:code [ fhir:v "panitumumab" ] ;
fhir:display [ fhir:v "Panitumumab" ]
  ] [
fhir:code [ fhir:v "adalimumab" ] ;
fhir:display [ fhir:v "Adalimumab (dostępny w terapii pacjentów od 4 r.ż.)" ]
  ] [
fhir:code [ fhir:v "etanercept" ] ;
fhir:display [ fhir:v "Etanercept (dostępny w terapii pacjentów od 6 r.ż.)" ]
  ] [
fhir:code [ fhir:v "infliksymab" ] ;
fhir:display [ fhir:v "Infliksymab" ]
  ] [
fhir:code [ fhir:v "iksekizumab" ] ;
fhir:display [ fhir:v "Iksekizumab (dostępny w terapii pacjentów od 6 r.ż.)" ]
  ] [
fhir:code [ fhir:v "sekukinumab" ] ;
fhir:display [ fhir:v "Sekukinumab (dostępny w terapii pacjentów od 6 r.ż.)" ]
  ] [
fhir:code [ fhir:v "ustekinumab" ] ;
fhir:display [ fhir:v "Ustekinumab (dostępny w terapii pacjentów od 6 r.ż.)" ]
  ] [
fhir:code [ fhir:v "ryzankizumab" ] ;
fhir:display [ fhir:v "Ryzankizumab" ]
  ] [
fhir:code [ fhir:v "guselkumab" ] ;
fhir:display [ fhir:v "Guselkumab" ]
  ] [
fhir:code [ fhir:v "certolizumab_pegol" ] ;
fhir:display [ fhir:v "Certolizumab pegol" ]
  ] [
fhir:code [ fhir:v "tyldrakizumab" ] ;
fhir:display [ fhir:v "Tyldrakizumab" ]
  ] [
fhir:code [ fhir:v "bimekizumab" ] ;
fhir:display [ fhir:v "Bimekizumab" ]
  ] [
fhir:code [ fhir:v "esketamina" ] ;
fhir:display [ fhir:v "Esketamina" ]
  ] [
fhir:code [ fhir:v "zanubrutynib" ] ;
fhir:display [ fhir:v "Zanubrutynib" ]
  ] [
fhir:code [ fhir:v "daratumumab" ] ;
fhir:display [ fhir:v "Daratumumab" ]
  ] [
fhir:code [ fhir:v "entrektynib" ] ;
fhir:display [ fhir:v "Entrektynib" ]
  ] [
fhir:code [ fhir:v "rytuksymab" ] ;
fhir:display [ fhir:v "Rytuksymab" ]
  ] [
fhir:code [ fhir:v "efgartigimod_alfa" ] ;
fhir:display [ fhir:v "Efgartigimod alfa" ]
  ] ) . #